RS52988B - Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-cikloheksankarboksilna kiselina - Google Patents

Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-cikloheksankarboksilna kiselina

Info

Publication number
RS52988B
RS52988B RS20130453A RSP20130453A RS52988B RS 52988 B RS52988 B RS 52988B RS 20130453 A RS20130453 A RS 20130453A RS P20130453 A RSP20130453 A RS P20130453A RS 52988 B RS52988 B RS 52988B
Authority
RS
Serbia
Prior art keywords
methyl
dimethyl
tetrahydro
tetrazol
phenyl
Prior art date
Application number
RS20130453A
Other languages
English (en)
Serbian (sr)
Inventor
David Michael Remick
Xinchao Chen
Scott Alan Frank
Steven Wayne Pedersen
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52988(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of RS52988B publication Critical patent/RS52988B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20130453A 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-cikloheksankarboksilna kiselina RS52988B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30
PCT/US2010/040125 WO2011002696A1 (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Publications (1)

Publication Number Publication Date
RS52988B true RS52988B (sr) 2014-02-28

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20130453A RS52988B (sr) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-cikloheksankarboksilna kiselina

Country Status (37)

Country Link
US (2) US8329688B2 (https=)
EP (1) EP2448933B1 (https=)
JP (1) JP5689875B2 (https=)
KR (1) KR101404893B1 (https=)
CN (1) CN102639528B (https=)
AR (1) AR077208A1 (https=)
AU (1) AU2010266537B2 (https=)
BR (1) BRPI1011931A2 (https=)
CA (1) CA2764425C (https=)
CL (1) CL2011003263A1 (https=)
CO (1) CO6480934A2 (https=)
CR (1) CR20110669A (https=)
DK (1) DK2448933T3 (https=)
DO (1) DOP2011000405A (https=)
EA (1) EA020600B1 (https=)
EC (1) ECSP11011551A (https=)
ES (1) ES2435293T3 (https=)
GT (1) GT201100321A (https=)
HR (1) HRP20130950T1 (https=)
IL (1) IL216655A (https=)
JO (1) JO2867B1 (https=)
MA (1) MA33385B1 (https=)
ME (1) ME01606B (https=)
MX (1) MX2011014024A (https=)
MY (1) MY157121A (https=)
NZ (1) NZ596820A (https=)
PE (1) PE20120538A1 (https=)
PL (1) PL2448933T3 (https=)
PT (1) PT2448933E (https=)
RS (1) RS52988B (https=)
SG (1) SG177413A1 (https=)
SI (1) SI2448933T1 (https=)
TN (1) TN2011000638A1 (https=)
TW (1) TWI450896B (https=)
UA (1) UA109409C2 (https=)
WO (1) WO2011002696A1 (https=)
ZA (1) ZA201108707B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005267436A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
ES2683350T3 (es) * 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
WO2014012401A1 (zh) * 2012-07-16 2014-01-23 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
WO2014119947A1 (en) 2013-01-31 2014-08-07 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
RU2703192C2 (ru) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (https=) 1970-12-15 1974-12-23
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
ATE316957T1 (de) 2001-04-30 2006-02-15 Pfizer Prod Inc Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate
BR0306208A (pt) 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006523218A (ja) 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2005097805A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
AU2005267436A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam

Also Published As

Publication number Publication date
MX2011014024A (es) 2012-04-20
IL216655A0 (en) 2012-02-29
CN102639528B (zh) 2014-07-16
DK2448933T3 (da) 2013-10-07
WO2011002696A1 (en) 2011-01-06
JP2012532106A (ja) 2012-12-13
EA201270099A1 (ru) 2012-05-30
DOP2011000405A (es) 2012-01-15
IL216655A (en) 2015-02-26
SG177413A1 (en) 2012-02-28
SI2448933T1 (sl) 2013-11-29
TW201113275A (en) 2011-04-16
ME01606B (me) 2014-09-20
EP2448933A1 (en) 2012-05-09
US20100331309A1 (en) 2010-12-30
ES2435293T3 (es) 2013-12-18
UA109409C2 (ru) 2015-08-25
ZA201108707B (en) 2013-05-29
CO6480934A2 (es) 2012-07-16
US8329688B2 (en) 2012-12-11
US8299060B2 (en) 2012-10-30
KR101404893B1 (ko) 2014-06-20
AU2010266537B2 (en) 2013-04-18
CA2764425A1 (en) 2011-01-06
NZ596820A (en) 2013-07-26
CA2764425C (en) 2015-01-06
EP2448933B1 (en) 2013-08-28
JO2867B1 (en) 2015-03-15
EA020600B1 (ru) 2014-12-30
PT2448933E (pt) 2013-10-29
ECSP11011551A (es) 2012-01-31
HRP20130950T1 (hr) 2013-11-22
KR20120027426A (ko) 2012-03-21
CL2011003263A1 (es) 2012-07-27
MA33385B1 (fr) 2012-06-01
AR077208A1 (es) 2011-08-10
PE20120538A1 (es) 2012-05-09
AU2010266537A1 (en) 2012-02-02
TWI450896B (zh) 2014-09-01
TN2011000638A1 (en) 2013-05-24
MY157121A (en) 2016-05-13
BRPI1011931A2 (pt) 2016-04-19
PL2448933T3 (pl) 2014-01-31
US20120058990A1 (en) 2012-03-08
JP5689875B2 (ja) 2015-03-25
CN102639528A (zh) 2012-08-15
GT201100321A (es) 2012-11-15
CR20110669A (es) 2012-03-16

Similar Documents

Publication Publication Date Title
RS52988B (sr) Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-cikloheksankarboksilna kiselina
CN112135612A (zh) 氨基酸化合物和使用方法
SK4442000A3 (en) Process and intermediates for preparing anti-cancer compounds
WO2010009402A9 (en) Nilotinib intermediates and preparation thereof
EP3998266A1 (en) Inhibiting creb binding protein (cbp)
CN104411704B (zh) 制备三唑化合物的方法
CA2652074C (en) Substituted carboxamides as group 1 metabotropic receptor antagonists
EP3176167A1 (en) Pyrazole derivative manufacturing method
US8772483B2 (en) Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
CN116018337A (zh) 铜绿假单胞菌毒力因子LasB抑制剂
ZA200302971B (en) Efficient process for the preparation of a factor Xa inhibitor.
HK1164877B (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
HK1164877A (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
CN108864113B (zh) 一种mdm2-hdac双靶点抑制剂、药物组合物及其制备和用途
CN106279018B (zh) β2-受体兴奋剂及其制备方法和应用
EP3587418B1 (en) Inhibitors of creb binding protein (cbp)
HK40018316A (en) Inhibitors of creb binding protein (cbp)
HK40018316B (en) Inhibitors of creb binding protein (cbp)